Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline

Fresenius has entered into an exclusive development agreement with WuXi Biologics, significantly expanding its future biosimilars pipeline. Building on the recent acquisition of mAbxience, the agreement adds development scale and flexibility to support long-term Biopharma growth and expand access to high-quality biologic medicines for patients worldwide.